GlassScriptPhysician profile
Sandra O Ogungbemi
NPI 1548676240
$7,725.46
in general payments reported to CMS, 2019-2025
11 companies · $3,893 in 2025
The $3,893 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $30.00 · 2021: $12.58 · 2022: $703 · 2023: $614 · 2024: $2,473 · 2025: $3,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,202 · Food and Beverage: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,201.93 |
| Food and Beverage | $778.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $5,901.50 | 2024-2025 | Monarch |
| Medtronic, INC. | $715.33 | 2021-2022 | |
| Intuitive Surgical, INC. | $554.79 | 2023-2025 | Da Vinci Surgical System |
| Ethicon INC. | $267.51 | 2024-2025 | Monarch Platform |
| Pinnacle Biologics, INC | $84.78 | 2023 | Photofrin |
| Regeneron Healthcare Solutions, INC. | $75.28 | 2023-2025 | Dupixent |
| Merz North America, INC. | $30.00 | 2020 | |
| Amgen INC. | $27.15 | 2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.78 | 2024 | |
| United Therapeutics Corporation | $22.29 | 2023 | |
| Precigen, INC. | $21.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Ogungbemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.